A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.

Key inclusion criteria:

1. Female, of non-childbearing potential, or male, both genders aged 18-55 years (bothinclusive) at the time of signing informed consent.

2. Body Mass Index (BMI) between 18.5 and 29.9 kg/m^2 (both inclusive) at screening.

3. Considered to be generally healthy based on the medical history, physicalexamination, and the results of vital signs, electrocardiogram and clinicallaboratory tests including inflammatory markers performed during the screeningvisit, as judged by the investigator

4. CYP2D6 phenotype:

5. For Part A and Part B: ultra-rapid (from cohort A3 forward and B1 forward),normal or intermediate CYP2D6 function

6. For Part C: CYP2D6 Poor Metaboliser function

Key exclusion criteria:

1. Any disorder/condition, which in the investigator's opinion might jeopardiseparticipant's safety or compliance with the protocol.

2. Known history of histamine intolerance or severe anaphylactic reactions

3. Abnormal values at screening for any of the following laboratory parameters

• Aspartate aminotransferase (AST) greater than Upper limit of normal (ULN)+10%.

• Alanine aminotransferase (ALT) greater than ULN +10%.

• Bilirubin (except if known Gilbert's syndrome) greater than ULN +10%.

• Creatinine greater than ULN.a.eGFR below 90 ml/min/1.73m^2

• Glycated haemoglobin (HbA1c) greater than or equal to 5.7% (39 mmol/mol).

4. CYP2D6 unknown phenotype